Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study
The United States (US) Expanded Access Program (EAP) to coronavirus disease 2019 (COVID-19) convalescent plasma was initiated in response to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19. While randomized clinical trials were in var...
Wedi'i Gadw mewn:
Prif Awduron: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Fformat: | Artigo |
Iaith: | Saesneg |
Cyhoeddwyd: |
2021
|
Mynediad Ar-lein: | https://doi.org/10.1371/journal.pmed.1003872 https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1003872&type=printable |
Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|